Overview
- Laboratorio Adium, under an agreement with Eli Lilly, introduced tirzepatide nationwide with 2.5 mg and 5 mg weekly pens now available and higher doses expected next year.
- The prescription therapy is indicated for adults with type 2 diabetes not adequately controlled or for chronic weight management in patients with a BMI of 30 or at least 27 with comorbidities.
- Clinical trials reported weight reductions of up to about 26% over 72 weeks, outperforming results seen with semaglutide at maximal doses.
- Pricing is steep, with reports around ARS 783,858 per month for 5 mg pens, though Adium announced benefit programs of up to 30% and payers signaled coverage focused on higher‑risk patients.
- The World Health Organization advises use only under medical supervision with diet and exercise and warns that high costs and limited supply mean the drugs will reach only a minority of eligible people.